Abstract
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have